Motilal Oswal's research report on Eris Lifesciences
Eris Lifesciences (ERIS) delivered in-line 4QFY23, led by steady growth in base business and improved performance of Oaknet as well as insulin franchise. Besides, addition of complimentary brands in medical/cosmetic dermatology from Glenmark Pharma and Dr. Reddy’s Lab is expected to enhance derma offerings going forward. We retain our earnings estimates for FY24/FY25 and value ERIS at 19x 12M forward earnings to arrive at our TP of INR720. We remain positive on ERIS aided by its: a) robust portfolio offerings in antidiabetes, cardiovascular and dermatology segments through organic as well as inorganic route, b) field force addition, which would expand coverage of specialist/consulting physicians, and c) improving operating leverage. Reiterate BUY.
Outlook
We retain our earnings estimates for FY24/FY25 and value ERIS at 19x 12M forward earnings to arrive at our TP of INR720.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
